Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 12/20 | 0.54 |
| ▸ | MMP2 | P08253 | 10/20 | 0.50 |
| ▸ | MMP9 | P14780 | 6/20 | 0.50 |
| ▸ | MMP3 | P08254 | 3/20 | 0.50 |
| ▸ | MMP1 | P03956 | 3/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.45 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 3/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872719 | 0.94 | MMP13 (0.56) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL4371646 | 0.88 | MMP13 (0.58) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL3876756 | 0.88 | MMP13 (0.58) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL1798737 | 0.82 | MMP13 (0.58) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL1798738 | 0.82 | MMP13 (0.58) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL3875821 | 0.80 | DUT (0.55) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL4293372 | 0.80 | MMP13 (0.49) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL4293377 | 0.80 | MMP13 (0.49) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL1798488 | 0.77 | ADAMTS7 (0.54) | MMP13MMP2MMP9MMP3MMP1 | |
| SCHEMBL1798485 | 0.77 | ADAMTS7 (0.54) | MMP13MMP2MMP9MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | claimed |
| EP-1461313-A1 | HUMAN ADAM-10 INHIBITORS | Exelixis, Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| WO-2003051825-A1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS, INC. (US) | 2003-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | MMP13 97/4885MMP2 203/4885MMP9 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.